Reduced frequency pembrolizumab immunotherapy: can the frequency of pembrolizumab treatment for non-small cell lung cancer be reduced without reducing its effectiveness? - Trial ISRCTN70247820
Access comprehensive clinical trial information for ISRCTN70247820 through Pure Global AI's free database. This Phase 3 trial is sponsored by Imperial College London and is currently status unknown. The study focuses on Non-small cell lung cancer. Target enrollment is 1750 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ISRCTN Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Imperial College London
Health Technology Assessment Programme
Timeline & Enrollment
Phase 3
Jan 14, 2022
May 31, 2027
Summary
To determine the optimal dose frequency of pembrolizumab amongst patients with NSCLC who have benefited from and completed 6 months of standard therapy. To determine the longest frequency of pembrolizumab treatment that has similar effectiveness in terms of the following when compared to standard 6 weekly pembrolizumab in NSCLC patients who have completed and benefitted from 6 months of standard treatment: • Overall survival (OS); • Progression free survival (PFS), or the length of time that a participant is alive and the cancer has not come back or grown significantly; • Overall response rate (ORR), or the proportion of participants for whom the cancer either disappears or shrinks significantly; • Duration of response (DoR), or, in the proportion of patients for whom the cancer either disappears or shrinks significantly, the length of time between the disappearance or shrinking significantly and the shrinking stopping or the cancer coming back or growing significantly; • Safety and tolerability, or the side effects that are related to pembrolizumab; • Quality of life (QoL); • Cost effectiveness.
ICD-10 Classifications
Data Source
ISRCTN Registry
ISRCTN70247820
Non-Device Trial